Firefly Neuroscience (AIFF) announced collaborating with Bright Minds Biosciences (DRUG) to analyze the data from its first-in-human Phase 1 study of its lead compound, BMB-101. The study demonstrated results of the qEEG data. During the EEG recording, subjects were seated with a U.S. Food and Drug Administration- approved 19 electrode EEG headset provided by Firefly strategic partner, Zeto Inc. Channels were sampled at 250 or 500 Hz and referenced to A1/A2 channels during recording. The EEG recording time was 10 minutes. There were four EEG recording timepoints: day 1 pre-dose and post-dose, and day 7 pre-dose and post-dose. Data was analyzed using the FireFly Neuroscience advanced EEG analysis platform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIFF:
- Firefly announces BNA will be used in Arrivo Bioventures’ Phase 1 study
- Firefly Neuroscience files to sell 2.56M shares of common stock for holders
- Firefly Neuroscience collaborates with Takeda, Novartis
- Firefly Neuroscience enters partnership with Zeto
- Firefly Neuroscience appoints Stella Vnook to board of directors
Questions or Comments about the article? Write to editor@tipranks.com